Close Menu
  • Business
  • World News
    • United States of America
    • Europe
    • Asia
    • Oceania
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Facebook X (Twitter) Instagram
Daily News
Facebook X (Twitter) Instagram
Subscribe
  • Home
  • Business

    What Size Skip Do You Need for Your Project?

    May 12, 2025

    Introduction to Share CFDs: Understanding the Basics

    December 2, 2024

    Importance of Proper Disposal in Spray Foam Removal

    August 26, 2024

    The Underlying Dynamics of Italy’s Euro: Economic Policies and Market Implications

    June 27, 2024

    The Pros and Cons of Payday Loans: Understanding the Risks and Benefits

    March 27, 2024
  • World News

    HNA Group Chairman Chen Feng Gives Speech at 2015 WTTC Global Summit: China Sees Huge Tourism Cooperation Opportunities with Europe

    October 24, 2020

    Greyrock Direct Fuel Production(TM) Recognized by the World Bank as Most Advanced Technology for Gas-to-Liquids

    September 28, 2020

    DJI to Open Flagship Store in Hong Kong

    August 29, 2020

    Micreos Secures Euros 12 Million for New Products Containing Staphefekt; Alternative to Antibiotics Can Help Millions

    June 18, 2020

    NetEase Debuts New Publicity Video in Shibuya, Triggers Speculation in Japan Game Industry

    April 19, 2020
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping
Daily News
Home»Business»RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus
Business

RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus

AndrewBy AndrewSeptember 2, 2014No Comments5 Mins Read0 Views
Facebook Twitter Pinterest Telegram LinkedIn Tumblr Copy Link Email
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link

Presented in ‘State of the Art and Featured Research Session’ at the 2014 European Society of Cardiology Congress

Resverlogix Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix delivered an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. In his presentation, entitled: ‘Effects of RVX-208 on MACE, ApoA-I and HDLs; a post-hoc analysis from the pooled SUSTAIN and ASSURE clinical trials’, Dr. Johansson reported that patients with cardiovascular disease (CVD) arising from atherosclerosis when given RVX-208 had a 55% (p=0.02) relative risk reduction (RRR) in MACE. More importantly, this beneficial effect of RVX-208 on patients with diabetes mellitus was accentuated with a RRR in MACE that was lowered by 77% (p=0.01). These observed reductions in MACE may stem from the ability of RVX-208 to significantly improve specific biomarkers of CVD risk measured in the SUSTAIN and ASSURE trials, including: higher levels of ApoA-I protein (p<0.01), an increase in HDL-C (p<0.001), more large HDL-particles (p<0.05) and growth in HDL particle size (p<0.05). The significant improvement in these biomarkers was in treated patients vs. placebo, which point to the beneficial effects of RVX-208 on reverse cholesterol transport.

RVX-208 acts via an epigenetic pathway and it is the first selective BET inhibitor being studied for treatment of CVD. The new information contained in the ESC presentation arose from the analysis of data pooled from the ASSURE and SUSTAIN clinical trials.

“The above findings are valuable to Resverlogix because they put the company in an advantageous position in the emerging field of therapeutics based on BET inhibition,” said Dr. Norman C.W. Wong, chief scientific officer of Resverlogix and also a practicing endocrinologist. “The data enhances the potential for RVX-208 to lower MACE in CVD patients and especially in those with diabetes mellitus. These key pieces of information will be used for the design of our next clinical trial that will continue the development of RVX-208 towards product registration.”

Donald McCaffrey, president and chief executive officer of Resverlogix added, “We are very pleased to have this data highlighted at the ESC Congress. It underscores our plans to diversify the development of RVX-208 by studying its activity in additional indications. Moving forward, in addition to the clinical paths in cardiovascular disease, diabetes mellitus and Alzheimer’s Disease, we are exploring other indications pertaining to chronic kidney disease (CKD), nonalcoholic steatohepatitis (NASH) and human immunodeficiency virus (HIV) lipodystrophy.”

About RVX-208

RVX-208 is a first-in-class small molecule that selectively inhibits BET bromodomains. RVX-208 functions via several mechanisms such as removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and then removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. Analysis of recent clinical trials data showed that RVX-208 significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD who have a low level of HDL and elevated hsCRP, a population with unmet medical need. ApoA-I enhancement and glucose lowering have been reported to exert beneficial effects in Alzheimer’s disease and diabetes mellitus, respectively. RVX-208 also has anti-inflammatory effects including effects on Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte chemotactic protein-1, factors known to be involved in atherosclerosis and plaque stability.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I. RVX-208 is a first-in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer’s disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company’s products, the availability of government and insurance reimbursements for the Company’s products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts:

Donald J. McCaffrey               Kenneth Lebioda
President and CEO                 SVP Business & Corporate Development
Resverlogix Corp.                 Resverlogix Corp.
Phone: 403-254-9252               Phone: 403-254-9252
Email: don@resverlogix.com        Email: ken@resverlogix.com

Media:

Matt Middleman, M.D.
Russo Partners, LLC
Phone: 212-845-4272
Email: matt.middleman@russopartnersllc.com

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Telegram Email Copy Link
Andrew

Related Posts

What Size Skip Do You Need for Your Project?

May 12, 2025

Introduction to Share CFDs: Understanding the Basics

December 2, 2024

Importance of Proper Disposal in Spray Foam Removal

August 26, 2024

Comments are closed.

Featured Posts

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Don't Miss!

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Top Posts

Importance of Proper Disposal in Spray Foam Removal

August 26, 202418 Views

Introduction to Share CFDs: Understanding the Basics

December 2, 202411 Views

PVC Windows and Doors still the most popular choice

October 12, 201211 Views

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 202510 Views
Don't Miss

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 20253 Mins Read10 Views

Swing trading offers a practical balance between day trading and long-term investing. It gives traders…

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Stay In Touch
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Subscribe to Updates

Get the latest creative news from SmartMag about art & design.

About Us
About Us

Daily News blog provides you the latest news, guide and tips, related information and issues about the Automotive, Business, Technology, Sports, Life & Style, News Photography, and Shopping etc.

Facebook X (Twitter) Instagram
Our Picks

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Most Popular

Mark Ingram wins 2009 Heisman Trophy

December 15, 20090 Views

Dubai receives bailout from Abu Dhabi

December 15, 20090 Views

North Korean weapons seized in Thailand

December 15, 20090 Views
Daily News
  • Home
  • About
  • Contact
  • Privacy Policy
Copyright © 2019-2025. Daily News..

Type above and press Enter to search. Press Esc to cancel.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT